Core Viewpoint - Yipinhong's wholly-owned subsidiary has received approval for clinical trials of a new drug, APH03621, which is a novel oral GnRH antagonist aimed at treating endometriosis, marking a significant development in the market as there are currently no approved oral GnRH antagonists in China [1] Company Summary - Yipinhong announced that its subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has obtained the Drug Clinical Trial Approval Notice from the National Medical Products Administration for APH03621 [1] - The drug is a new type of oral, non-peptide small molecule GnRH antagonist [1] - The clinical trials for APH03621 are set to commence shortly [1] Industry Summary - APH03621 is intended for the treatment of endometriosis, a condition that currently lacks approved oral GnRH antagonists in the domestic market [1]